Sentence examples for biologic interest from inspiring English sources

Although the ability of patients with MDS to show an erythroid response to epoetin is of biologic interest, because of high costs and the limited response rate in transfusion-dependent patients, epoetin therapy, with or without G-CSF, cannot be regarded as a definitive therapy for the anemia of MDS.

These RNAi libraries are useful for identifying single genes of biologic interest, or genes that encode potential targets for conventional drug development.

PLUNC, uteroglobin and P4HB were selected from the list of twenty-three candidates based on their biologic interest, molecular weight, and antibody availability.

A perfect-gene approaches the smallest biologic quantity for which there is clearly a biologic interest and we can calculate the impact of adding such a feature to the dataset on the SWISS score.

For the comparative analysis between high grade serous carcinomas of different BRCA1/2 status, a less stringent set of gene filtering criteria was employed for the 37 serous tumors and 3 fallopian tube samples in an attempt to identify miRNA showing more subtle variation that may be of biologic interest.

Data for many other pollutants of biologic interest may be sparse or nonexistent (e.g., EC and air toxics).

Taken together with the considerable costs of biologics, interest in monitoring the therapy has risen not only for the purpose of identifying markers that will serve as end-points for successful treatment, but also for timely cessation or switching of therapy in those unlikely to respond.

However, many of these tools require the direct modification of the active biologic of interest [92].

We identified patients included in the Medco PBM database with one or more claims for a biologic of interest (abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, or tocilizumab) from July 1 , 2007 to July 31, 2012.

Observation was ended at either 1.0 year after the start of the observation period, or on the date of death of a patient, loss to follow up, enrollment in clinical trials, when therapy with a biologic of interest was discontinued for more than 90 days, or on 5 March 2012, whichever came first.

Biologics of interest included abatacept, adalimumab, etanercept, infliximab and rituximab.